The restructuring plan will be pushed back again by the choice of whether to run up to the medical adjustment

Runda Medical's restructuring was thugly denied yesterday because of inadequate disclosure of relevant information about the underlying company. The audit opinions given by the merger and reorganization committee of the CSRC are as follows: The information disclosed by the applicant materials concerning the restructuring of the underlying company and the changes in state-owned property rights, internal control and business compliance is insufficient and does not conform to the relevant provisions of Articles 4, 11 and 43 of the Measures for the Administration of Major Assets Reorganization of Listed Companies.
the Shanghai News reporter learned from the company, Runda Medical will be the restructuring program to further optimize the adjustment. Company Secretary Lu Xiaoyan said in an interview that the restructuring of the underlying asset earnings quality is better, and conducive to improve the company's market layout, improve the comprehensive service capacity. The Company will optimize and adjust the relevant programs in accordance with the above-mentioned audit opinions, and choose the opportunity to continue to promote the restructuring. Whether this reorganization will have an impact on the company's business development. The company's shares resumed trading on December 27.
Looking back at the restructuring plan, Runda Medical intends to buy 70% of Suzhou Run win, 70% of Shanghai Runlin, 25% of Hangzhou Yidan, 60% of Shanghai Weikang and 55% of Shanghai Ruimei by way of issuing shares and paying cash, with a total transaction price of 1,137 million yuan.
same time, the Company intends to raise no more than 535 million yuan from the non-public offering of shares to no more than 10 specific objects, some of which will be used to pay the cash equivalent of the transaction and the remainder to cover the related expenses. Upon completion of the transaction, the listed company will hold 70% of Suzhou Run win, 70% of Shanghai Runlin, 70% of Hangzhou Yidan, 60% of Shanghai Weikang and 100% of Shanghai Ruimei.
It is understood that the proposed purchase of the company Suzhou Run win, Shanghai Runlin and Hangzhou Yidan are leading enterprises in the regional or professional field, through its acquisition, Runda Medical will further enhance the market competitiveness in the relevant regional or specialized areas. Shanghai Weikang and Shanghai Ruimei are professional service providers, through this transaction, Runda Medical will further enhance the storage logistics services capacity and laboratory information services capacity, strengthen the comprehensive service content and service capabilities.
financial data, the five underlying companies are highly profitable. Among them, Suzhou Run won net profit of RMB33.1295 million, RMB37.4926 million and RMB27.9914 million in 2016, 2017 and January-August 2018, respectively. During the same period, Shanghai Runlin's net profit was RMB16,962.2 million, RMB25,887.8 million and RMB1,778.49 million. Hangzhou Yidan's net profit was RMB40,633.6 million, RMB42.7968 million and RMB32.4102 million.
this year, Runda Medical has continued to focus on the integrated service business of medical laboratories, accelerate the promotion of the overall integrated service business, and optimize the service content. In the first three quarters of this year, the Company achieved operating income of RMB4.336 billion, up 48.17% YoY, and net profit attributable to shareholders of listed companies was RMB243 million, up 45.12% YoY. Revenue growth is understood to be mainly due to the expansion of the business. Lu Xiaoyan further said that initially, the company's business sectors will maintain stable growth throughout 2018. (Shanghai Securities News)